title: OMERACT endorsement of measures of outcome for studies of acute gout.
abstract: OBJECTIVE
  To determine the extent to which participants at the Outcome Measures in Rheumatology (OMERACT) 11 meeting agree that instruments used in clinical trials to measure OMERACT core outcome domains in acute gout fulfill OMERACT filter requirements of truth, discrimination, and feasibility; and where future research efforts need to be directed.
  
  
  METHODS
  Results of a systematic literature review and analysis of individual-level data from recent clinical studies of acute gout were presented to OMERACT participants. The information was discussed in breakout groups, and opinion was defined by subsequent voting in a plenary session. Endorsement was defined as at least 70% of participants voting in agreement with the proposition (where the denominator excluded those participants who did not vote or who voted "don't know").
  
  
  RESULTS
  The following measures were endorsed for use in clinical trials of acute gout: (1) 5-point Likert scale and/or visual analog scale (0 to 100 mm) to measure pain; (2) 4-point Likert scale for joint swelling; (3) 4-point Likert scale for joint tenderness; and (4) 5-point Likert scale for patient global assessment of response to treatment. Measures for the activity limitations domain were not endorsed.
  
  
  CONCLUSIONS
  Measures of pain, joint swelling, joint tenderness, and patient global assessment in acute gout were endorsed at OMERACT 11. These measures should now be used in clinical trials of acute gout.
authors: From Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Medicine, University of Otago, Wellington; Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; SDG LLC, Cambridge, Massachusetts,; Duke University School of Medicine, Durham, North Carolina, USA, and Duke-National University of Singapore Graduate Medical School, Singapore; Schlosspark-Klinik Teaching Hospital of the Charité, University Medicine Berlin, Berlin, Germany; University of Sydney Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, Sydney, Australia; Stanford University Division of Immunology and Rheumatology, Portolo Valley, California, USA; University of Ottawa, London, Ontario, Canada; University of Michigan Medical School, Ann Arbor, Michigan, USA; University of Auckland, Department of Molecular Medicine and Pathology, Grafton, Auckland, New Zealand; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Maastricht University Medical Center, Division of Rheumatology, and Caphri Research Institute, University Maastricht; VU University Medical Center, Amsterdam, the Netherlands; University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Rheumatology, University of Florida, Gainsville, Florida, USA.
authors: Jasvinder A
authors: JA
authors: Singh
authors: William J
authors: WJ
authors: Taylor
authors: Nicola
authors: N
authors: Dalbeth
authors: Lee S
authors: LS
authors: Simon
authors: John
authors: J
authors: Sundy
authors: Rebecca
authors: R
authors: Grainger
authors: Rieke
authors: R
authors: Alten
authors: Lyn
authors: L
authors: March
authors: Vibeke
authors: V
authors: Strand
authors: George
authors: G
authors: Wells
authors: Dinesh
authors: D
authors: Khanna
authors: Fiona
authors: F
authors: McQueen
authors: Naomi
authors: N
authors: Schlesinger
authors: Annelies
authors: A
authors: Boonen
authors: Maarten
authors: M
authors: Boers
authors: Kenneth G
authors: KG
authors: Saag
authors: H Ralph
authors: HR
authors: Schumacher
authors: N Lawrence
authors: NL
authors: Edwards
mesh_terms: D002986:Clinical Trials as Topic; D004185:Disability Evaluation; D006073:Gout / Q000188:drug therapy* / Q000503:physiopathology; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D017063:Outcome Assessment, Health Care; D010147:Pain Measurement; D012219:Rheumatology; D016896:Treatment Outcome
chemical_list: D006074:Gout Suppressants
keywords: GOUT; OUTCOME MEASURES; PSYCHOMETRICS